S-1/A: Cardiff Lexington Seeks Nasdaq Uplisting with $6M Offering

Cardiff Lexington Corporation is offering 1.5 million shares of common stock at an assumed price of $4.00 per share, contingent on its uplisting to The Nasdaq Capital Market, despite ongoing financial challenges including recurring net losses and a going concern doubt.

Summary

• Cardiff Lexington Corporation is a targeted healthcare holding company focused on acquiring and building middle-market niche health care clinics, primarily in orthopedics, spine care, and pain management.
• The company is offering 1,500,000 shares of common stock at an assumed public offering price of $4.00 per share, aiming to raise approximately $4.9 million in net proceeds (or $5.7 million if the over-allotment option is fully exercised).
• The closing of this offering is contingent upon the company's common stock being listed on The Nasdaq Capital Market under the symbol CDIX.
• All current revenue is derived from its healthcare subsidiary, Nova Ortho and Spine, LLC, which focuses on plaintiff-related care for uninsured patients involved in lawsuits.
• The company also owns a real estate company, Edge View Properties, Inc., which holds 27 acres of land in Idaho with no current development plans, expecting to eventually sell the property.
• For the nine months ended September 30, 2025, revenue increased by 70.18% to $8,763,314 from $5,149,416 in the same period of 2024.
• The company reported a net loss of $2,821,471 for the nine months ended September 30, 2025, compared to a net loss of $2,392,657 for the same period in 2024.
• For the year ended December 31, 2024, the company had a net loss of $3,302,999, a significant decrease from a net income of $3,028,394 in 2023.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report, citing sustained operating losses and an accumulated deficit of $76,533,799 as of September 30, 2025.
• The primary use of proceeds from the offering is for the repayment of certain debt and for working capital and general corporate purposes, including future acquisitions.
• A 1-for-3 reverse stock split was implemented on January 12, 2026, reducing outstanding common stock from 41,152,612 to 13,718,365 shares.
• Two stockholders, including the CEO and former Chairman, will collectively hold approximately 68% of the total voting power after the offering.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, evidenced by recurring net losses, negative operating cash flow, a substantial accumulated deficit, and a 'going concern' warning from its auditors. While revenue growth in the healthcare segment is positive, it's overshadowed by declining settlement rates and material weaknesses in internal controls. The proposed capital raise and Nasdaq uplisting are critical but highly uncertain, and the immediate dilution for new investors is substantial. The high concentration of voting power among a few stockholders also presents a governance risk.

Positives

• Healthcare segment revenue increased by 70.18% to $8,763,314 for the nine months ended September 30, 2025, compared to the same period in 2024.
• Gross profit for the nine months ended September 30, 2025, increased by 126.17% to $5,445,371 from $2,407,651 in the prior year period.
• The company has a clear acquisition and value creation strategy focused on profitable niche small to mid-sized healthcare companies.
• Management believes there is significant opportunity for organic growth and expanded utilization of current healthcare facilities, which are operating at 35% capacity as of September 30, 2025.
• The company's focus on plaintiff-related care, primarily funded by bodily injury, general liability, and personal injury protection policies, partially insulates it from declining Medicare/Medicaid and traditional health insurance reimbursements.
• The company has a track record of delivering strong growth through organic expansion, new contract additions, and selective acquisitions.
• Management is focused on clinical excellence, rigorous recruiting, physician-led culture, and continuous enhancement of skills through development programs.
• The company has made significant investments in scalable technology systems to improve clinical results, client metrics, and reduce patient care costs.

Negatives

• The company's independent registered public accounting firm included a going concern explanatory paragraph due to sustained operating losses and an accumulated deficit of $76,533,799 as of September 30, 2025.
• Net losses increased to $2,821,471 for the nine months ended September 30, 2025, from $2,392,657 for the same period in 2024.
• The company experienced a net loss of $3,302,999 for the year ended December 31, 2024, a significant decline from a net income of $3,028,394 in 2023.
• The typical accounts receivable collection cycle is extended (18 to 24 months), creating liquidity and cash flow constraints, increased exposure to bad debt, and dependence on external financing.
• The company lacks systematic processes and resources to support the aging of its accounts receivables, leading to inefficiencies and higher operational costs, with significant expenditures expected to remedy this.
• Revenue for the year ended December 31, 2024, decreased by 30.23% to $8,270,126 from $11,853,266 in 2023, attributed to service mix changes, hurricane impacts, and efforts to accelerate cash settlements at lower rates.
• The settlement realization rate for accounts receivable decreased from 49% historically to 44% for the nine months ended September 30, 2024, and further to 42% as of September 30, 2025, due to accepting lower settlement amounts for faster payment.
• Total other expense, net, significantly increased to $4,618,361 for the nine months ended September 30, 2025, primarily due to increased interest expense on the line of credit.
• The company has identified material weaknesses in its internal control over financial reporting, including lack of formal documentation, proper segregation of duties, and sufficient technical accounting resources for complex transactions.
• Two stockholders, including the CEO and former Chairman, will collectively exercise approximately 68% of the total voting power, potentially reducing the ability of minority stockholders to effect certain corporate actions.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to recurring operating losses and an accumulated deficit.
• Extended accounts receivable collection cycle (18-24 months) creates liquidity and cash flow constraints, increases bad debt exposure, and necessitates external financing.
• Lack of systematic processes and resources for managing accounts receivables can lead to inefficiencies, higher operational costs, and inaccuracies in financial reporting.
• The acquisition strategy exposes the company to substantial risks, including failure to identify material problems during due diligence, overpaying for assets, and difficulties in integrating acquired businesses.
• Failure to manage a growing and changing business could materially adversely affect business, prospects, financial condition, and results of operations.
• Competition for acquisition targets may force the company to acquire businesses at sub-optimal prices or forego opportunities.
• Inability to successfully fund acquisitions due to unavailability of equity or debt financing on acceptable terms could impede the acquisition strategy.
• Future success is dependent on the management teams of its businesses, and the loss of key personnel could materially adversely affect financial condition and operations.
• Potential conflicts of interest may arise if the company engages in transactions with target businesses having relationships with executive officers, directors, or their affiliates.
• The company is a holding company and relies on distributions from subsidiaries, which may be restricted by financing arrangements or legal/regulatory limitations.
• Future credit facilities may expose the company to additional risks associated with leverage and inhibit operating flexibility.
• The company may change its management and acquisition strategies without stockholder consent, potentially leading to riskier business activities.
• If the company ceases to control and operate its businesses or engages in certain investment-related activities, it may be deemed an investment company under the Investment Company Act.
• The ability to grow the healthcare business through organic expansion is dependent on many factors, including capacity, occupancy, suitable sites, and regulatory permits.
• Changes to payment rates or methods of third-party payors, including government healthcare programs, could adversely affect operating margins and revenues.
• An increase in uninsured or underinsured patients or deterioration in collectability of accounts could harm results of operations.
• Failure to timely or accurately bill for services could negatively impact net revenue and cash flow.
• Healthcare facilities face intense competition for patients from other providers, some with greater financial resources or tax exemptions.
• Performance depends on the ability to recruit and retain quality physicians, nurses, and medical support staff, facing nationwide shortages and increased labor costs.
• Failure to comply with extensive healthcare laws and government regulations could result in civil or criminal penalties or significant operational changes.
• Loss of accreditation for existing facilities or failure to receive accreditation for new ones could render them ineligible for Medicare/Medicaid reimbursement.
• The company could be subject to lawsuits, including medical malpractice and professional liability claims, for which it may not be fully reserved.
• The real estate business is subject to demand fluctuations, adverse weather conditions, and unforeseen environmental or geological issues.
• Decreases in the market value of real estate investments could reduce results of operations.
• Changes in tax laws, taxes, or fees may increase the cost of development or sale of property.
• The company may incur environmental liabilities with respect to its real estate assets.
• Uninsured losses relating to real property or excessively expensive insurance premiums may adversely affect stock value.
• Limited trading in common stock prior to the offering and potential failure to maintain Nasdaq listing could impair liquidity and market price.
• The market price of common stock may be highly volatile, leading to potential loss of investment.
• New investors will experience immediate and substantial dilution as a result of this offering.
• Future issuances of common stock or convertible securities, or expiration of lock-up agreements, could cause the market price to decline and dilute holdings.
• Rule 144 sales in the future may have a depressive effect on the stock price.
• Future issuances of debt or preferred stock could rank senior to common stock, adversely affecting returns.
• If common stock becomes subject to penny stock rules, it would be more difficult to trade shares.
• Lack of research reports from securities industry analysts could negatively affect market price and trading volume.
• Anti-takeover provisions in charter documents and Nevada law could make an acquisition more difficult and limit stockholder influence.

Future Outlook

Management believes that current working capital and expected additional financing should be sufficient to fund operations and satisfy obligations for at least one year. Additional funds ranging from $5 million to $10 million are required for continued operations and to execute the business plan, including acquiring additional businesses. The company intends to raise capital for acquisitions primarily through equity and debt financings. The company will continue to evaluate its estimate of settlement realization rates quarterly, based on historical data and discussions with legal and billing partners. The company expects to make significant expenditures over 18-24 months to implement enhanced practices for managing accounts receivables.

Management Comments

• Management believes, based on our operating plan, that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy our obligations as they come due for at least one year.
• Management does not currently have any plans to develop this property (Edge View) and expects to eventually sell the property.
• We believe that the most important factors relating to the overall utilization of a facility include adequate working capital, the quality and market position of the facility and the number, quality and specialties of physicians providing patient care within the facility.
• Management estimates that our twelve facilities are operating at 35% capacity as of September 30, 2025, indicating an opportunity for organic growth.
• We believe that our processes related to managed care contracting, billing, coding, collection and compliance have driven a strong track record of efficient revenue cycle management.
• We believe that our significant investments in scalable technology systems will facilitate additional cost reductions and efficiencies.
• Management is in continuous discussions with prospective investors and believes the raising of capital will allow the Company to fund its cash flow shortfalls and pursue new acquisitions.

Industry Context

The company operates in the highly competitive healthcare sector, specifically targeting niche orthopedic, spine care, and pain management clinics. Its focus on plaintiff-related care for uninsured patients, with revenue primarily from bodily injury and personal injury protection policies, provides some insulation from declining Medicare/Medicaid and traditional health insurance reimbursements. However, this model leads to extended accounts receivable cycles, a significant challenge. The industry is also affected by increasing consolidation of insurance and managed care companies, which can reduce negotiation leverage for providers. The company's acquisition strategy aims to capitalize on a fragmented market of small to mid-sized healthcare companies, aligning with broader trends of consolidation and efficiency seeking in healthcare.

Comparison to Industry Standards

• The company's extended accounts receivable collection period of 18 to 24 months is significantly longer than the typical 30, 60, or 90-day increments seen in traditional product or service businesses, posing unique liquidity and bad debt risks.
• The company's historical loss rate of less than 1.0% for uncollected accounts receivable, despite the long collection cycle, suggests a relatively effective recovery mechanism through letters of protection, which may be better than some uninsured patient collection rates in other healthcare segments.
• The company's 35% facility capacity utilization as of September 30, 2025, indicates substantial underutilization compared to industry benchmarks for profitable healthcare facilities, which typically aim for much higher occupancy rates to maximize operational efficiency and profitability.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition, or operating results.
• The company is subject to claims and suits in the ordinary course of business, including those arising from services provided, personal injury claims, professional liability claims, billing and marketing practices, employment disputes, and contractual claims.
• Physicians, hospitals, and other healthcare participants are subject to an increasing number of medical malpractice lawsuits.
• The company is subject to various government investigations and litigation, and from time to time, some facilities receive notices of potential non-compliance with laws and regulations from federal and state agencies.

Related Party Transactions

• The company assumed amounts due to previous owners who are current managers of Edge View (real estate subsidiary) in connection with its acquisition on July 16, 2014. The balance due from these previous owners was $4,979 as of September 30, 2025, and December 31, 2024, which is due on demand and non-interest bearing.
• Short-term advances from Daniel Thompson, former Chairman of the Board, totaling $120,997 as of December 31, 2023, were repaid in full during the year ended December 31, 2024.
• Alex Cunningham, CEO, has an employment agreement effective January 1, 2025, with an initial base salary of $885,000 per year, eligible for annual bonuses and automatic increases upon successful acquisitions or Nasdaq uplisting and capital raise. Past due amounts owed to Mr. Cunningham accrue interest at 5% quarterly. Total outstanding accrued compensation was $2,215,500 as of September 30, 2025.
• Daniel Thompson, former Chairman, had an employment agreement amended January 1, 2025, with a base salary of $700,000 for 2025 and eligibility for performance bonuses. Past due amounts owed to Mr. Thompson accrue interest at 5% quarterly. Total outstanding accrued compensation was $2,320,500 as of September 30, 2025.
• Matthew T. Shafer, CFO, has an employment agreement effective January 2, 2024, with an annual base salary of $228,000 (increased to $250,800 effective January 1, 2025), eligible for achievement bonuses and annual stock option grants. No outstanding accrued compensation as of September 30, 2025.
• Management agreement effective May 31, 2021, for Nova principals (three doctors) includes annual base salaries ($372,000, $450,000, $372,000) and a collective annual cash bonus and stock equity conditioned on achieving financial performance goals. No accrual for bonus was recorded for the nine months ended September 30, 2025, or the year ended December 31, 2024, as objectives were not met.
• On August 25, 2023, a $5,000 convertible promissory note was issued to Alex Cunningham, CEO, for operating expenses, which was paid in full in August 2024.
• On January 19, 2024, 62,500 shares of series I preferred stock were issued to Daniel R. Thompson and Alex Cunningham each for $250,000 bonus compensation for fiscal year 2023.
• On January 31, 2024, 5,000 shares of series I preferred stock were issued to Matthew Shafer, CFO, for $20,000.
• On May 25, 2023, 3,150 shares of series B preferred stock were issued to Zia Choe, former Chief Accounting Officer.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the public offering and future equity raises. Existing shareholders will experience immediate and substantial dilution. The 'going concern' doubt and recurring losses pose a high risk to investment value. The concentration of voting power among a few key individuals may limit the influence of minority shareholders.
• **Employees**: The company's ability to attract and retain high-quality medical professionals and support staff is crucial for its healthcare business. Equity incentive plans are in place to align employee interests with the company's success. However, the company's financial instability could impact job security or compensation in the long term.
• **Customers (Patients)**: The company's focus on plaintiff-related care for uninsured patients means their access to services is tied to legal settlements. The extended accounts receivable cycle and potential for bad debt could indirectly affect service continuity or quality if not managed effectively. The focus on clinical excellence aims to benefit patient outcomes.
• **Suppliers/Creditors**: The extended accounts receivable cycle and reliance on external financing, coupled with the 'going concern' doubt, present risks for creditors. The company's ability to meet its debt obligations depends on future cash flow and successful capital raises. The line of credit with DML HC Series, LLC is a significant financial arrangement.
• **Management**: Management's compensation is tied to performance goals and equity incentives. The success of the Nasdaq uplisting and acquisition strategy is critical for their financial incentives and the company's overall stability. They bear the primary responsibility for addressing the 'going concern' issues and improving financial performance.

Next Steps

• Complete the public offering of 1,500,000 shares of common stock.
• Achieve listing of common stock on The Nasdaq Capital Market.
• Repay certain debt obligations, including a $85,000 settlement promissory note and potentially $80,000 in convertible promissory notes, upon the closing of the offering.
• Utilize net proceeds for working capital and general corporate purposes, including future acquisitions.
• Implement enhanced practices to better capture and manage the aging of accounts receivables, expecting 18-24 months for full operationalization.
• Continue to evaluate and update settlement realization rate estimates quarterly.
• Address identified material weaknesses in internal control over financial reporting.
• Pursue strategic acquisitions of outpatient Orthopedic Surgery Centers and related Clinics in identified favorable states.
• Capitalize on organic growth opportunities at existing facilities, which are operating at 35% capacity.
• Enhance operational efficiencies and productivity through initiatives like efficient scheduling, use of mid-level providers, and improved compensation programs.

Key Dates

Recommendation

Cardiff Lexington Corporation presents an extremely high-risk investment profile. The company's independent auditors have issued a 'going concern' warning, indicating substantial doubt about its ability to continue operations. This is supported by a significant accumulated deficit of over $76 million and consistent net losses, despite recent revenue growth in its healthcare segment. The company's unique business model, relying on plaintiff-related care, results in an exceptionally long accounts receivable collection cycle (18-24 months), which severely strains liquidity and cash flow, and exposes it to high bad debt risk. Furthermore, the company admits to lacking systematic processes for managing these critical receivables and expects significant expenditures to address this. While a Nasdaq uplisting and capital raise are planned, they are contingent and uncertain. New investors face immediate and substantial dilution. The concentration of voting power with a few insiders also raises governance concerns. Given these severe financial and operational challenges, the stock carries a 'strong sell' recommendation, as the risks of capital loss far outweigh any potential upside.

Keywords

Healthcare Holding Company, Orthopedics, Spine Care, Pain Management, SEC Filing, S-1/A, Public Offering, Nasdaq Uplisting, Common Stock, Convertible Notes, Warrants, Accounts Receivable, Going Concern, Financial Performance, Acquisition Strategy, Risk Factors, Corporate Governance, Nevada Corporation, Nova Ortho and Spine, Edge View Properties, Medical Facilities, Capital Raise, Dilution, Share-based Compensation